← boardnext 2027-05
VOR
Vor Biopharmadistress 2/10 · well-funded / low risk$18.97-3%today-62% from 52w high
Oncology 2Immunology / Inflammation 1
Lead: primary Sjögren's disease · target BAFF/APRIL
Revenue
pre-revenue
Liquidity
$492M
Runway
3.3 yrs
Shares 1y
-57%
Price & events
+9.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.8%
1D
+9.4%
1W
+27.7%
1M
+29.8%
3M
+14.3%
6M
-54.6%
1Y
-0.2%
2Y
-92.7%
5Y
-97.5%
All
Overview
- Market Cap
- $1.03B
- Volume
- 41.74K
- 52 Week Range
- $6.86 – $50.00
- Total Shares
- 54.19M
- Float Shares
- 35.67M
- Short %
- 17.09%
- % Held by Insiders
- 4.27%
- % Held by Institutions
- 69.58%
- RVOL
- 0.03x
- Beta
- 1.70
Pipeline stages · 3 programs
Telitacicept
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
VOR33, Mylotarg
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
VCAR33
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-05 Estimated 50% readout ~2027-07-15 | Phase 3 | Telitacicept | Generalized Myasthenia Gravis | — | recruiting |
| 2028-12 Estimated 50% readout ~2029-02-14 | Phase 3 | Telitacicept | Primary Sjogren's Disease | — | recruiting |
| 2025-05-28 | Phase 1/2 | VOR33, Mylotarg | Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | 67 | terminated |
| 2025-05-28 | Phase 1/2 | VCAR33 | Leukemia, Myeloid, Acute | 38 | terminated |
| 2025-01-06 | Phase 3 | Telitacicept, Placebo | Systemic Lupus Erythematosus | 91 | terminated |
Catalyst news & presentations · 7
- first half of 2027Guided 55%readoutPhase 3telitacicept · Global Phase 3 topline dataSEC 8-K
- 2026-08-14Estimated 45%earningsEarningsEarnings releaseyahoo
- first half of 2026trial initiationsecondaryPhase 3telitacicept · Global Phase 3 trial initiationSEC 8-K
- second half of 2025readoutPhase 1/2trem-cel · Updated clinical data from Phase 1/2a VBP101 trial in combination with MylotargSEC 8-K
- October 29, 2025 at 10:50AM PTconferencedata presentationsecondaryPhase 3telitacicept · Oral presentation of 48-week Phase 3 results at AANEM 2025.SEC 8-K
- first half of 2025readoutPhase 1/2VCAR33 ALLO · Updated clinical data from Phase 1/2 VBP301 trialSEC 8-K
- 2025-06-25partnershiptelitacicept · Exclusive license from RemeGen for development and commercialization outside Greater ChinaSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $38 (+100% upside) · 8 analysts
- 2026-05-18HC Wainwright & Co.Buy
- 2026-05-14WedbushNeutral
- 2026-04-15HC Wainwright & Co.Buy
- 2026-03-31WedbushNeutral
- 2026-03-30JefferiesBuy
- 2026-03-19Wells FargoOverweight
Competitors — BAFF/APRIL
- VERAVera Therapeutics, Inc.$2.5B · D4
Recent news
- 2026-07-22Ra Capital Management’s fund sells $4,206 in Vor Biopharma stock - Investing.com
- 2026-07-22Form 13D/A VOR BIOPHARMA INC. For: 22 July By Investing.com - Investing.com Nigeria
- 2026-07-22Form 4 Vor Biopharma Inc For: 22 July By Investing.com - Investing.com Nigeria
- 2026-07-21RA Capital exercises 2,100,000 Vor Biopharma (VOR) pre-funded warrants - Stock Titan
- 2026-07-21Vor Biopharma Inc. (VOR) holder exercises 2,100,000 pre-funded warrants - Stock Titan
- 2026-07-21Price to sales forward of Vor Biopharma Inc. – NASDAQ:VOR - TradingView
- 2026-07-17Can Vor Biopharma’s (VOR) New Board Appointment Reshape Its Late-Stage Commercialization Strategy? - Sahm
- 2026-07-17Price to earnings forward of Vor Biopharma Inc. – NASDAQ:VOR - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.